Triplet Appears Active in Relapsed/Refractory and Newly Diagnosed AML
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
Diagnosis & Disease Information
Rezlidhia Approved for Relapsed/Refractory AML With IDH1 Mutation
Olutasidenib is a small-molecule inhibitor of mutated IDH1.
Dietary Methionine Depletion May Inhibit Acute Myeloid Leukemia Progression
Researchers sought to determine the impact of dietary depletion of methionine on the progression of AML.
FLT3-ITD Measurable Residual Disease Is a Clinically Relevant Biomarker for Disease Risk Assessment in AML
Researchers sought to determine whether FLT3-ITD MRD would be a biomarker for dynamic disease risk assessment in acute myeloid leukemia.
Adding Gilteritinib to Azacitidine Does Not Improve OS, EFS in Newly Diagnosed AML
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Oral Azacitidine Confers Survival Benefits in Patients With Acute Myeloid Leukemia
Researchers evaluated oral azacitidine vs placebo in patients with newly diagnosed AML.
Racial Disparities Identified in AYA Patients With Acute Myeloid Leukemia
Researchers sought to identify racial disparities and their effects in AYA patients with AML.
Machine Learning Shows Promise in Therapeutic Decision-Making for Patients With Acute Myeloid Leukemia
Researchers sought to determine whether a machine learning-based approach would help clinicians determine treatment regimens for newly diagnosed patients with AML.
Azacitidine May Improve Outcomes in a Subset of Patients With AML
Researchers sought to determine the safety and efficacy of oral azacitidine vs placebo among patients with AML.
- Loading...
Loading...
Next post in SOHO 2022
Loading... 
Loading...